Catalyst
Slingshot members are tracking this event:
Phase 3 MONARCH 2 Data Evaluating Abemaciclib in Patients with Relapsed/Refractory HR+/HER2- Breast Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| LLY |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 20, 2017
Occurred Source:
http://www.prnewswire.com/news-releases/lilly-announces-phase-3-monarch-2-breast-cancer-study-of-abemaciclib-met-primary-endpoint-of-progression-free-survival-300425928.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Data, Monarch 2 Study, Monarch 3 Study, Breast Cancer, Abemaciclib
